SG Americas Securities
AZN icon

SG Americas Securities’s AstraZeneca AZN Stock Holding History

SG Americas Securities’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-40,000
Closed -$224K – 3477
2017
Q2 		$224K Buy
+40,000
New +$2.61M ﹤0.01% 2340

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

SG Americas Securities's AZN Position: Q2 2026 in Review

SG Americas Securities reduced its AstraZeneca (AZN) stake by 41% in Q2 2026, selling an estimated $618K and leaving 4,728 shares worth $897K. The position accounts for ﹤0.01% of the portfolio, ranked #1952.

SG Americas Securities first reported a position in AZN in Q4 2016 and has held it in 35 quarters since. The position peaked at $23.3M in Q4 2025. 1,507 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • SG Americas Securities held 4,728 shares of AstraZeneca worth $897K as of Q2 2026.
  • SG Americas Securities sold 3,285 AstraZeneca shares in Q2 2026, an estimated $618K.
  • AstraZeneca made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #1952 holding.
  • SG Americas Securities first reported a position in AstraZeneca in Q4 2016 and has held it in 35 quarters since.
  • SG Americas Securities's AstraZeneca position peaked at $23.3M in Q4 2025.
  • 1,507 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.